Identifying drug target is key to the development of a new drug. While project approval of new drug, the Company performs comprehensive analysis from the angle of market demand, and advantages and disadvantages of existing representative target drugs, and select competitive programs of high druggability but difficult to develop for further research based on the scientifically verified drug targets, with an aim to addressing the unmet clinical needs. The Company tracks and adopts the internationally most state-of-the-art biological targets, and competes with the products in development for same targets that are difficult to develop and pertaining to major indications in bad need of therapeutic drugs clinically. Its issuer products have entered the first echelon or are ranking among the top.

Drug molecular design is the basis of research and development of modern innovational small molecular drugs, which refers to building molecular operating process of a new chemical entity with activity predictable through scientific conception and rational strategy. The Company’s new drug research team has experience of research and development at international companies for approximately 20 years.

After obtaining leading compound molecules of good biological activity by screening with computer-aided drug design technology, the Company needs to further modify and optimize compound structure with the core pharmacophore reserved based on the physicochemical properties and pharmacokinetic characteristics of leading compound molecules such as solubility, membrane permeability, metabolic stability, body distribution, and target missing. After years of exploration and technology practice accumulation, the Company has improved the physicochemical properties and pharmacokinetic characteristics of leading compound through optimization design of leading compound, prodrug design, soft drug design and crystal optimization study, to meet various clinical needs.

The Company has established a sound DMPK evaluation system for comprehensive evaluation and screening of candidate compounds for in vivo and in vitro activity, mechanism of action, and pharmacokinetic and toxicological characteristics. Pharmacokinetic evaluation platform functions to determine dynamic change of drug concentration in the body via quantitative research of the process of drug in living body (absorption, distribution, metabolism and excretion) together with explaining dynamic rule of drugs in the body using mathematics principles and methods. The Company not only has gathered pharmacokinetic data of plenty of compounds, but also works to predict pharmacokinetic characteristics of compounds by virtue of AI platform (such as big data analysis of molecular fingerprint), so as to help compound screening.

Traditional early stage clinical trials mostly are based on experience and trial-and-error method. The Company applies model-informed drug development (MIDD) that is still in the early stage in China to build model simulation technology to integrate and conduct quantitative research on mass of data and information about disease mechanisms, pharmacology and pharmacodynamics interaction, so as to guide clinical plan design of drugs, exploration of early clinical dose, and selection of Phase II recommended dose, and support clinical development strategy of products.

The Company has a clinically and professionally experienced clinical team. The team has built an effective clinical design and development platform, enabling the company to perform international multi-center clinical development in China and overseas. On the basis of action mechanism and molecular properties of drugs in development, epidemiological characteristics of diseases, clinical diagnosis and treatment and the needs of patients and referring to clinical data of similar targets or indications, the team has developed differentiated clinical plans for each patient subject. The team has completed patient recruitment with high quality and advanced clinical trials by rationally setting inclusion and exclusion criteria and selecting study endpoint under the help of third-party institute, having realized high clinical development efficiency. The Company has formulated differentiated clinical trial schemes pertaining to each main product or indication and multistage-integrated trial design, and clinical test is promoted fast thereby.